Meckler Jeffrey A
Meckler Jeffrey A's purchase track record
How the stock did after each of Meckler Jeffrey A's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/18/2022 | INDP | $19K | -2.0% | +17.3% | +5.7% |
| 9/6/2022 | INDP | $54K | -25.5% | -32.5% | +2.0% |
| 6/6/2022 | INDP | $52K | -7.2% | -30.6% | -3.0% |
| 11/18/2021 | INDP | $65K | -11.5% | -46.9% | -17.1% |
| 9/14/2021 | INDP | $84K | -13.4% | -54.9% | -4.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Indaptus named among top small-cap healthcare performers. Indaptus Therapeutics was highlighted in a recent report as one of five smaller health care stocks that outperformed Moderna in September. The stock is currently trading near the upper end of its 52-week range, reflecting this recent strength. This inclusion in a performance-based list draws attention to the company's recent market activity relative to larger peers.
Transaction History
| TVTX | ▲ Buy | Option Exercise | 10,000 | $174K | 9/10/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 10,000 | $265K | 9/10/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,700 | $111K | 9/10/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,200 | $79K | 9/10/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 14,000 | $944K | 9/10/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 3,100 | $211K | 9/10/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 8,000 | $131K | 5/4/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 8,000 | $360K | 5/4/2026 | View on chart |
| INDP | ▲ Buy | Grant | 216,617 | $440K | 12/22/2025 | View on chart |
| INDP | ▲ Buy | Grant | 6,068 | $50K | 7/27/2025 | View on chart |
| TVTX | ▲ Buy | Grant | 6,500 | $0 | 5/15/2025 | View on chart |
| INDP | ▲ Buy | Grant | 42,553 | $50K | 11/25/2024 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 40,000 | $419K | 9/30/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 40,000 | $562K | 9/30/2024 | View on chart |
| INDP | ▲ Buy | Grant | 84,932 | $155K | 8/8/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 6,500 | $0 | 5/8/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 4,500 | $0 | 5/17/2023 | View on chart |
| INDP | ▲ Buy | Open Market | 9,600 | $18K | 11/21/2022 | View on chart |
| INDP | ▲ Buy | Open Market | 400 | $705 | 11/18/2022 | View on chart |
| INDP | ▲ Buy | Open Market | 10,308 | $29K | 9/8/2022 | View on chart |
| INDP | ▲ Buy | Open Market | 8,632 | $22K | 9/7/2022 | View on chart |
| INDP | ▲ Buy | Open Market | 1,060 | $3K | 9/6/2022 | View on chart |
| INDP | ▲ Buy | Open Market | 19,727 | $52K | 6/6/2022 | View on chart |
| TVTX | ▲ Buy | Grant | 3,000 | $0 | 5/11/2022 | View on chart |
| INDP | ▲ Buy | Open Market | 11,187 | $65K | 11/18/2021 | View on chart |
| INDP | ▲ Buy | Open Market | 12,000 | $84K | 9/14/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data
Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.